We found that enterostatin (VPDPR), an anorexigenic peptide for a high-fat diet, signiˆcantly reduces serum cholesterol levels after oral administration of 100 mg W kg for 3 days in mice fed a high cholesterol-cholic acid diet. DPR, a peptide fragment of VPDPR, also had hypocholesterolemic activity at a dose of 50 mg W kg. Food intake was not suppressed under these dietary conditions. Fecal excretion of cholesterol and bile acids was increased signiˆcantly by both VPDPR and DPR. Interestingly, DPR induced hypocholesterolemic eŠects just two hours after a single oral administration at a dose of 100 mg W kg.
Enterostatin (VPDPR) is released from the amino terminus of procolipase during its conversion to colipase, 1, 2) and inhibits food intake after central or peripheral administration in animals fed a highfat diet. [3] [4] [5] [6] [7] [8] Furthermore, VPDPR reduces serum triglyceride levels 3) and in‰uences energy metabolism in rats fed a high-fat diet by activating the sympathetic drive in brown adipose tissue, to increase thermogenesis. 9) VPDPR reportedly reduces intake of high fat foods via stimulation of the speciˆc m-opioid agonist b-casomorphin (1-7), 10) indicating that an anti-opioid mechanism may be responsible for the anorectic eŠect. Morphine reportedly elevates serum cholesterol levels.
11) Furthermore, we demonstrated previously that VPDPR inhibits analgesia induced by the m-opioid agonist morphine.
12) Therefore, we investigated the eŠects of VPDPR on serum cholesterol levels.
Male mice of the ddy strain (Otsubo Exp. Animals, Nagasaki, Japan) weighing about 14 g were used. Experimental protocols involving laboratory animals were approved by the ethical committee of the Graduate School of Agriculture, Kyoto University. The room temperature was maintained at 239 C with a 12-h light (07:00-19:00) and dark cycle. The mice were housed in groups of four per standard plastic cage and had free access to food and water. The mice were fed a commercial stock diet (MF; Oriental Yeast Co., Tokyo, Japan) for 4 days during adaptation to the new environment, and then fed a puriˆed high cholesterol-cholic acid diet. The composition of the basal diet was based on the formula recommended by the American Institute of Nutrition, in weight percent as follows; casein, 20; DL-methionine, 0.3; corn starch, 43.50; sucrose, 10.0; cellulose, 5.0; corn oil, 5.0; mineral mixture (AIN-76), 3.5; vitamin mixture (AIN-76), 1.0; choline bitartate, 0.20; cholesterol, 1.0; cholic acid, 0.5; coconut oil, 10. Mice were fed this high cholesterol-cholic acid diet for 3 days. Peptides were dissolved in saline adjusted to pH 7.0 and then given orally every day at 11:00. Blood was collected by cardiac puncture 24 hours after the third dose was administered. Total and HDL cholesterol in serum were measured by an enzymatic method using a commercially available kit (Cholesterol E-test Wako and HDL-C, Wako Pure Chemical Ind., Ltd., Osaka, Japan). The reported levels of LDL and VLDL were the calculated diŠerences between total and HDL cholesterol.
VPDPR signiˆcantly reduced serum cholesterol levels after oral administration at a dose of 100 mg W kg (Fig. 1a) . On the other hand, serum triglyceride levels were unaŠected in mice under these highcholesterol dietary conditions (data not shown). Both LDL and VLDL cholesterol levels were decreased, while the HDL-cholesterol level was not changed (Fig. 1b, c) . It was reported that VPDPR and its fragment DPR inhibited secretion of insulin after peripheral administration in rats. 13) Then the eŠects of DPR on serum cholesterol levels were also investigated. As shown in Fig. 2 , DPR reduced total and LDL＋VLDL cholesterol levels in serum after oral administration at a dose of 50 mg W kg (Fig. 2) . Thus, DPR was two-fold more potent at inducing hypocholesterolemia than VPDPR on the basis of weight.
Lipid levels in serum, feces, and liver were then measured in mice housed in individual cages (Table 1) . VPDPR and DPR did not induce anoretic eŠects in mice fed a high cholesterol-cholic acid diet; food intake and body weight gains tended to increase in the VPDPR-or DPR-treated groups, though not signiˆcantly. Feces were collected for 48 hours after the second oral dose of the peptides, and lyophilized. Fecal cholesterol and bile acids were extracted 3 times with 100 times volumes of ethanol at 759 C for 1 hour. After extraction, the supernatant was recovered by centrifugation. The supernatant was dried, and then dissolved in methanol. Fecal cholesterol and bile acids were measured by an enzymatic method using the Cholesterol E-test Wako and Total Bile Acid-test Wako (Wako Pure Chemical Ind., Ltd., Osaka, Japan). Liver cholesterol was extracted by the method of Folch et al., 14) and measured using the Cholesterol E-test Wako. As shown in Table 1 , the serum cholesterol level was signiˆcantly decreased in mice given VPDPR or DPR. Cholesterol and bile acids in feces were signiˆcantly higher in the VPDPR-or DPR-treated groups than the control group. Amount of feces were higher in VPDPR-or DPR-treated mice. This might re‰ect an increase of food intake in these group. It should be noted that not only the total amount of cholesterol and bile acids in feces but also their concentrates per gram of feces increased in mice given these peptides. The liver cholesterol level was unaŠected by VPDPR-or DPRtreatment.
Next, we investigated how rapidly the peptides reduce serum cholesterol levels. Peptides were orally administered to mice fed a high cholesterol-cholic acid diet for 6 days. Blood was collected 2 hours after peptide administration. Interestingly, DPR induced a hypocholesterolemic eŠect after a single oral dose of 100 mg W kg, while VPDPR was ineŠective even at the dose of 200 mg W kg (Fig. 3) . The rapid hypocholesterolemic eŠect of DPR might be mediated, at least in part, by stimulation of bile acids secretion. In fact, DPR stimulated bile acids secretion in rats while VPDPR did not (unpublished result). On the other hand, VPDPR induced a hypocholestero-lemic eŠect after oral administration for 3 days (Fig. 1) . Thus, the hypocholesterolemic eŠect of VPDPR might be due to its conversion to DPR in vivo. Alternatively, VPDPR might reduce cholesterol levels by a diŠerent mechanism. High-molecularweight core peptides derived from soybean proteins reportedly lower serum cholesterol by binding to bile acids to inhibit their reabsorption. 15) However, binding of VPDPR to bile acids may be unlikely due to the repulsion between the negative charges of both molecules. Nagaoka et al. reported that the low molecular weight peptide IIAEK derived from b-lactogloblin supresssed cholesterol absorption to induce hypocholesterolemia in rats. 16) It is uncertain whether the observed increase in fecal cholesterol was caused by the inhibition of cholesterol absorption by VPDPR.
We recently reported that the anti-analgesic activity of VPDPR is mediated by corticosterone released from the adrenal cortex. 17) However, the hypocholesterolemic eŠect of VPDPR or DPR was not inhibited by the glucocorticoid receptor antagonist RU486, and was observed in adrenalectomized mice (data not shown). These results suggest that the hypocholesterolemic eŠect is not mediated by corticosterone.
Thus, we report here for theˆrst time that VPDPR and DPR have hypocholesterolemic eŠects in mice after oral administration of 100 mg W kg and 50 mg W kg, respectively. DPR is more potent than VPDPR due to its lower eŠective dose and rapid onset of e‹cacy.
